COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
|
|
- Curtis Perry
- 6 years ago
- Views:
Transcription
1 COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
2 Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial Disclosure Company Grants / Research Support Speakers Honorarium Consulting Fees Patents Other None Astrazeneca, BMS, Takeda Boeringher Ingelheim, Abbott Eli Lilly, Amgen, Mylan, Janssen Forest Laboratories, J&J, Merck, Novartis, Pfizer, Servier, Sanofi None None None
3 Mitigating Potential Bias Only published data will be presented in this program and recommendations will be based on published Guidelines
4 Learning Objectives: By the end of this workshop you will be able to: 1. Make appropriate diagnosis 2. Understand appropriate testing 3. Be able to incorporate guidelines into the management of your patients 4. Understand the role of new therapies for the management of your patients
5 Percent Change in Age-Adjusted Death Rates, U.S., (Proportion of 1965 Rate)
6
7
8 Air trapping
9 Mr. CO 76 year old man Short of breath Had Negative Cardiac workup Smoker 40 pk years Coughs most days some sputum Meds: ARB, Statin, ASA, Vitamins
10 Global Strategy for Diagnosis, Management and Prevention of COPD Diagnosis of COPD SYMPTOMS shortness of breath chronic cough sputum EXPOSURE TO RISK FACTORS tobacco occupation indoor/outdoor pollution SPIROMETRY: Required to establish diagnosis 2013 Global Initiative for Chronic Obstructive Lung Disease
11 11
12 Focus on Vital Capacity (VC) 12
13 Spirometry: Normal Trace Showing FEV 1 and FVC 5 FVC Volume, liters FEV 1 = 4L FVC = 5L FEV 1 /FVC = Time, sec 2013 Global Initiative for Chronic Obstructive Lung Disease
14 Spirometry: Mr. CO 5 Normal 4 Volume, liters FEV 1 = 1.8L FVC = 3.2L FEV 1 /FVC = 0.56 Obstructive < Time, seconds 2013 Global Initiative for Chronic Obstructive Lung Disease
15 Mr. CO Walking can t keep up with his wife
16 Assessing Disability in COPD
17 Mr. CO FEV1 is 70% predicted
18 Global Strategy for Diagnosis, Management and Prevention of COPD Classification of Severity of Airflow Limitation in COPD* based on FEV 1 GOLD 1: Mild GOLD 2: Moderate GOLD 3: Severe GOLD 4: Very Severe FEV 1 > 80% predicted 50% < FEV 1 < 80% predicted 30% < FEV 1 < 50% predicted FEV 1 < 30% predicted *Based on Post-Bronchodilator FEV Global Initiative for Chronic Obstructive Lung Disease
19 Global Strategy for Diagnosis, Management and Prevention of COPD Classification of Severity of Airflow Limitation in COPD* based on FEV 1 GOLD 1: Mild GOLD 2: Moderate GOLD 3: Severe GOLD 4: Very Severe FEV 1 > 80% predicted 50% < FEV 1 < 80% predicted 30% < FEV 1 < 50% predicted FEV 1 < 30% predicted *Based on Post-Bronchodilator FEV Global Initiative for Chronic Obstructive Lung Disease
20 Global Strategy for Diagnosis, Management and Prevention of COPD Classification of Severity of Airflow Limitation in COPD* based on FEV 1 GOLD 1: Mild Mr. CO FEV1 = 70% FEV 1 > 80% predicted GOLD 2: Moderate 50% < FEV 1 < 80% predicted GOLD 3: Severe GOLD 4: Very Severe 30% < FEV 1 < 50% predicted FEV 1 < 30% predicted *Based on Post-Bronchodilator FEV Global Initiative for Chronic Obstructive Lung Disease
21 Mr. CO 5 years he had 3 exacerbations
22 What is the impact of exacerbations on mortality? 50% of COPD patients are dead within 4 years of being admitted for first time with COPD 1 A= No Exacerbations B= 1-2 Exacerbations C= > 3 Exacerbations 1.Suissa S, Dell Aniello S, Ernst P. Thorax. doi: /thorax.jnl , 2.Soler-Cataluna JJ, et al. Thorax. 2005;60:
23 Suissa S et al. Thorax 2012;67:
24 Suissa S et al. Thorax 2012;67:
25 Daily rates of death (per per day) in the 90-day period after onset of severe chronic obstructive pulmonary disease exacerbation. Suissa S et al. Thorax 2012;67: Copyright BMJ Publishing Group Ltd & British Thoracic Society. All rights reserved.
26 LAMA vs Placebo for Exacerbation 80 * Probability of exacerbation (%) Hazard ratio: 0.86 CI: *p<0.001 No. at risk Month Tiotropium Placebo Tashkin DP, et al. N Engl J Med. 2008;359:
27 LAMA vs LAMA + LABA Formoterol + Tiotropium Change from baseline in trough FEV 1 (ml) Trough FEV 1 : Change from baseline * n=108 n=118 n=127 n=121 n=106 n=121 n=121 n=129 Week 4 Week 8 Week 12 Last visit * * Mean change in symptom score Total COPD Symptom Score * AM * PM AM/PM average * Formoterol (12 µg b.i.d.) + tiotropium (18 µg o.d.) Tiotropium (18 µg o.d.) *p<0.05; p<0.001 vs. tiotropium; sum of scores for dyspnea (0 = none to 4 = severe), wheezing, cough, and chest ghtness (0 = none to 3 = very uncomfortable). Tashkin DP, et al.: COPD 2009; 6(1):17 25.
28 TORCH ICS vs LABA vs Combo Calverley PMA et al. N Engl J Med 2007;356:
29 LAMA vs LAMA + ICS + LABA % reduction in rate of severe exacerbation Ratio: 0.38 (95% CI: ) P < BUD/FORM + TIO PBO + TIO Exacerbations/patient Poisson regression Days since randomisation BUD/FORM=budesonide/formoterol (320/9 μg bid); PBO = placebo; TIO = tiotropium (18 μg od) Welte T, et al. Am J Respir Crit Care Med. 2009;180:
30 Global Strategy for Diagnosis, Management and Prevention of COPD Combined Assessment of COPD GOLD FEV1 4 3 ICS (C) + LABA or LAMA ICS + LABA (D) and/or LAMA >2 <50% Predicted Exacerbations 2 1 SAMA prn (A) or SABA prn LABA (B) or LAMA 1 0 mmrc 0-1 CAT < Global Initiative for Chronic Obstructive Lung Disease Symptoms mmrc > 2 CAT > 10
31 Treatment of Stable COPD 2017 Global Initiative for Chronic Obstructive Lung Disease
32 Bronchodilator LAMA or LABA 2 Bronchodilators LAMA + LABA Bronchodilators + ICS LAMA + LABA + ICS
33 Pharmacotherapy Indicated for COPD in Canada BRONCHODILATORS SHORT ACTING BETA 2 AGONISTS LONG ACTING BETA 2 AGONISTS SHORT ACTING ANTICHOLINE RGICS LONG ACTING ANTICHOLINERGICS Umeclidinium (bromide) INCRUISE Ellipta 62.5 mcg CORTICOSTERIODS/LONG ACTING BETA 2 AGONISTS Budesonide/Formoterol (fumarate) ANTICHOLINERGICS AND LONG ACTING BETA 2 AGONISTS Ipratropium (bromide)/ Salbutamol (sulfate) Glycopyrronium (bromide)/ Indacaterol (maleate) Umeclidinium (bromide)/ Vilanterol (trifenatate) Tiotropium (bromide)/ Olodaterol (hydrochloride) Aclidinium (bromide)/ Formoterol (fumarate) COMBIVENT Respimat 20/100 mcg Chart not representative of all approved COPD medications Canada. INSPIOLTO Respimat 2.5/2.5 mcg accessed June 24, 2015 DUAKLIR Genuair 400/ 12 mcg
34 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 34
35 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 35
36 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 36
37 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 37
38 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 38
39 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) LABA SABA Device Long-acting beta 2 agonist Efficacy Safety Short-acting beta 2 agonist Formoterol Salmeterol Indacaterol Vilanterol Olodaterol Salbutamol Terbutaline Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Striverdi (Respimat) Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 39
40
41 1 Adapted from : Newman SP, et al. Lung Deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicine: Comparison of Respimat with conventional metereddose inhalers with and without spacer devices. Chest1998;113:
42 DPI (Diskus) Slide the lever away from you as far as it will go Breathe out until lungs are empty Place the mouthpiece in mouth and close lips firmly around it Breathe in as fast & as hard as you can until lungs are full Hold breath for 10s Breathe out Adapted from asthmameds.ca
43 43
44 44
45 45
46 Respimat
47 Turbuhaler
48 Devices Green & Go Red & Done Feedback on successful inhalation Audible click when patient is inhaling sufficiently Control window turns red when inhalation is complete Tudorza Genuair Product Monograph, 2013
49 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) LABA SABA Device Long-acting beta 2 agonist Efficacy Safety Short-acting beta 2 agonist Formoterol Salmeterol Indacaterol Vilanterol Olodaterol Salbutamol Terbutaline Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Striverdi (Respimat) Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 49
50 LAS39: Change from baseline FEV 1 by timepoint over 24 hours at Day 1 *p<0.05 aclidinium vs tiotropium This study alone does not constitute a head-to-head study to support comparative claims of aclidinium vs tiotropium. Beier et al. COPD 2013
51 Aclidinium reduces COPD exacerbation (any severity) rates (24 weeks): ATTAIN 1.6 Placebo Aclidinium 400 µg BID 1.39 COPD exacerbations (/pt/year) % p< % p< Healthcare Resource Utilization criteria EXACT criteria Reproduced with permission Jones et al. CHEST 2012
52 Canadian RWE A retrospective observational propensity-matched cohort study Healthcare utilisation in the first year after initiating ICS/LABA therapy Courses of oral steroids/year (0.72, 1.00) ED visits/year (0.58, 0.97) Hospital admissions/year (0.47, 0.81) Addition of a tiotropium prescription/year (0.57, 0.89) In Canada, 5255 COPD patients were treated with an ICS/LABA before matching 3969 (76%) patients in this cohort used FLU/SAL 36% had exacerbations pre-index More bud/form vs. flu/sal pats. had a first ICS/LABA initiated by a specialist (8% more) Antibiotics were not evaluated as a definition of exacerbations Patients were tracked for 1 year Blais L et al. Clin Ther 2010; 32 (7): 1320 These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.
53 COPD Exacerbations BUD/FOR (n=2734) or FLU/SAL (n=2734) Rate ratio (95% CI) All exacerbations ** NNT = (0.69, 0.79) Oral steroids ** 0.74 (0.68, 0.81) Antibiotics ** BUD/FOR 0.70 (0.66, 0.75) Hospitalisations ** NNT = 16 SAL/FLU 0.71 (0.65, 0.78) Emergency visits * 0.79 (0.71, 0.89) Event rate per 100 patient years Adjusted yearly rates of healthcare utilisation events were compared using Poisson regression analysis. **P<0.0001; *P= for difference. CI, confidence intervals; BUD/FOR, budesonide/formoterol; FLU/SAL, fluticasone/salmeterol These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph. Larsson et al. J Intern Med 2013; DOI: /joim.12067
54 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) LABA Device Long-acting beta 2 agonist Efficacy Formoterol Salmeterol Indacaterol Vilanterol Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) SABA Safety Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 54
55 Pneumonia Risk in COPD Patients (Stratified by ICS Type) Meta analysis of ICS use (studies 1 3 yr duration) Corticosteroid Type Fluticasone (16 studies) Budesonide (7 studies) Mometasone (1 study) Risk Ratio HR (95%CI) 1.67 ( )* 1.19 ( ) [ns] 2.00 ( ) [ns] Corticosteroid Safer Corticosteroid Harmful *statistically significant increase with fluticasone p< [ns] = no statistically significant increase in risk detected The elderly and those with more severe disease and lower FEV1s are at the highest risk of pneumonia. Singh S, Loke YJ. Curr Opin Pulm Med. 2010; 16:
56 Cumulative Pneumonia Rate vs Time Post Index Cumulative pneumonia rate per 100 patients Fluticasone/salmeterol group Any pneumonia Hospitalised pneumonia Budesonide/formoterol group Any pneumonia Hospitalised pneumonia All pneumonias RR 1.73 (1,57; 1.90) P<0.001 NNT 23 Hospitalised pneumonias RR 1.74 (1,56; 1.94) P<0.001 NNT Years Adjusted yearly pneumonia event rates compared using Poisson regression analysis. Janson et al. BMJ 2013;346:f3306 DOI: /bmj.f3306 These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.
57 An Immunosuppressant / Infection hypothesis Fluticasone /salmeterol ASL Mucosa/Lung tissue ASL = Airway surface liquid Budesonide Budesonide/GCS-receptor Bacteria Fluticasone Fluticasone/GCS-receptor These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph. 1. Wedzicha JA et al. AJRCCM Calverley et al. Chest 2011;139: Patterson C et al Respiratory Research 2012,13:40 4. Ek A et al Allergy (1999). 54: Miller-Larsson et al. AJRCCM (2000). 162: Johnsson M et al Allergy (1995) 50:s Dalby C, et al. Respir Res (2009); 10:104
58 Dissolution Time in Airway Fluid Water solubility (μg/ml) Dissolution time (human BAL fluid in vitro) Flunisolide 140 <2 min Triamcinolone 21 n.d. acetonide Budesonide 16 6 min Beclomethasone 17-propionate Fluticasone 17-propionate Beclomethasone dipropionate 16 n.d >8h 0.13 >5h Högger and Rohdewald, Rev Contemp Pharm 1998 n.d.= no data These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.
59 Dissolution Time in Airway Fluid Water solubility (μg/ml) Dissolution time (human BAL fluid in vitro) Flunisolide 140 <2 min Triamcinolone 21 n.d. acetonide Budesonide 16 6 min Beclomethasone 17-propionate Fluticasone 17-propionate Beclomethasone dipropionate 16 n.d >8h 0.13 >5h Högger and Rohdewald, Rev Contemp Pharm 1998 n.d.= no data These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.
60 Safety: Hydrolysis of LAMAs Gavaldà et al Two major acid and alcohol metabolites are inactive Sentellas et al, 2010 Alberti et al, 2010
61 ICS + LABA Advair (Diskus) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 61
62 ICS + LABA Symbicort (Turbuhaler) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 62
63 ICS + LABA Breo (Ellipta) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 63
64 LAMA + LABA Anoro (Ellipta) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 64
65 LAMA + LABA Ultibro (Breezhaler) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 65
66 LAMA + LABA Stiolto Respimat Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 66
67 LAMA + LABA Duaklir (Genuair) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 67
68 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS LAMA LAAC LABA SABA SAMA Inhaled corticosteroid Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Long-acting beta 2 agonist Short-acting beta 2 agonist Short-acting antimuscarinic Budesonide Fluticasone Proprionate Fluticasone Furoate Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Device Efficacy Formoterol Salmeterol Indacaterol Vilanterol Safety Salbutamol Terbutaline Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Ventolin (Diskus) Ipratropium Atrovent Bricanyl (Turbuhaler) 68
69 COPD Risk & Smoking Cessation 1,5,7 Never smoked or not susceptible to smoke FEV 1 (% of value at age 25) Smoked regularly and susceptible to effects of smoke Disability Death Stopped smoking at 45 (mild COPD) Stopped smoking at 65 (severe COPD) Age (years) Fletcher C et al. Br Med J. 1977;1:
70 Peter COPD Lin MD CCFP Maze Director Primary Care Initiatives Canadian Heart Research Centre Keep COPD in DDx Tools for Assessing Risk Medications: Bronchodilators vs ICS Step up: Single then dual then triple Rx Decide based on: Device, Efficacy, Safety Avoid Exacerbations
COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationHSN S FORMULARY ALTERNATIVES FOR STABLE COPD. Which drug comes with which device?
HSN S FORMULARY ALTERNATIVES FOR STABLE COPD Which drug comes with which device? Long-Acting Bronchodilators LAMAs LABAs LONG ACTING MUSCARINIC ANTAGONISTS Blocks acetylcholine-mediated bronchoconstriction
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationCOPD 2016 What to do with all these New Inhalers?
COPD 2016 What to do with all these New Inhalers? Planning committee Content Experts Clinical reviewers Paul Hernandez MDCM FRCPC, Department of Respirology, QEII Health Sciences Centre, Associate Professor,
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationHe is still Short of Breath Is there any new puffer? Saidul Ansary
He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationTake My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care
Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationImpact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,
More informationReport generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationMichelle Zeidler, MD, MS
7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA
More informationWhat is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018
What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationCOPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center
COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationThese lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece.
Lung Function Tests This leaflet only gives you general information about the lung function (breathing) tests. However, it does not replace the need for the personal advice from the health care professional.
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More information12:00 Autonomic Drugs 12:00. Autonomic Drugs
Autonomic Drugs Autonomic Drugs 12:04 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS PILOCARPINE HCL 5 MG ORAL TABLET 00002216345 SALAGEN 1.4298 PYRIDOSTIGMINE BROMIDE 60 MG ORAL TABLET 00000869961 MESTINON
More informationShared System of Care COPD/Heart Failure
Shared System of Care COPD/Heart Failure Learning Session 2 www.pspbc.ca Agenda Introduction (35) Sharing Experiences(10) Medication (60, 40 didactic and 20 discussion) MOA Breakout Break (15) PSM Support
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationAsthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives
Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationBalanced information for better care. Helping patients with COPD breathe easier
Balanced information for better care Helping patients with COPD breathe easier COPD is the third-leading cause of death in the U.S., following cancer and heart disease 1 FIGURE 1. Women now have a higher
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationFDCs for CO PD: From Famine to a Feast of Therapeutic Choices
FDCs for CO PD: From Famine to a Feast of Therapeutic Choices LAURA RUNKEL, PhD Associate Director, CNS, AutoImmune/Inflammation, Ophthalmology Historically, there have been few therapies developed for
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationDr Stephen Child. Chief Medical Officer Southern Cross Health Society Auckland
Dr Stephen Child Chief Medical Officer Southern Cross Health Society Auckland 7:00-7:55 GlaxoSmithKline Breakfast Session - Hot Topics in Airways Disease: COPD and Asthma Hot Topics in Airways Disease:
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationGOLD 2017: cosa c è di nuovo
GOLD 2017: cosa c è di nuovo Antonio Spanevello Università degli Studi dell Insubria, Varese Dipartimento di Medicina e Chirurgia Istituti Clinici Scientifici Maugeri, IRCCS, Tradate Dipartimento di Medicina
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More information